Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.09
+0.01 (0.21%)
Sep 2, 2026, 11:48 AM EDT - Market open
Entrada Therapeutics Revenue
Entrada Therapeutics had revenue of $898.00K in the quarter ending June 30, 2026, a decrease of -53.95%. This brings the company's revenue in the last twelve months to $4.69M, down -94.10% year-over-year. In the year 2025, Entrada Therapeutics had annual revenue of $25.42M, down -87.94%.
Revenue (ttm)
$4.69M
Revenue Growth
-94.10%
P/S Ratio
54.40
Revenue / Employee
$30,829
Employees
152
Market Cap
255.46M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.42M | -185.36M | -87.94% |
| Dec 31, 2024 | 210.78M | 81.77M | 63.38% |
| Dec 31, 2023 | 129.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Niagen Bioscience | 129.08M |
| Compugen | 74.00M |
| Invivyd | 58.37M |
| Surrozen | 11.51M |
| Adagene | 9.29M |
| Whitehawk Therapeutics | 7.15M |
| YD Bio | 510.36K |
TRDA News
- 16 days ago - Entrada Therapeutics price target raised to $11 from $10 at Roth Capital - TheFly
- 4 weeks ago - Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04) - TheFly
- 4 weeks ago - Entrada Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Entrada Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Entrada Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Entrada Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts